Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
On September 1, 2021, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of outstanding shares and voting rights. The company has 79,294,402 ordinary shares and 6,784 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,087,342, while exercisable voting rights amount to 80,068,767. This disclosure is in compliance with French regulations to ensure transparency in shareholding. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment.
On September 17, 2021, Innate Pharma announced results from AstraZeneca's COAST Phase 2 trial presented at the ESMO Congress 2021. The interim analysis revealed that monalizumab combined with durvalumab significantly improved progression-free survival (PFS) and objective response rate (ORR) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy. AstraZeneca plans to initiate a registrational study based on these promising results, highlighting the potential of monalizumab as a groundbreaking treatment targeting NKG2A receptors on tumor-infiltrating immune cells.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced promising results from the TELLOMAK trial, which showed a 35% overall global response rate for lacutamab in patients with mycosis fungoides. Financially, the company reported €15.7 million in revenue for H1 2021, a decline from €36.7 million in H1 2020, and a net loss of €23.7 million. Their cash position stands at €159.4 million.
Innate also launched new clinical trials for lacutamab and showcased advancements in their ANKET™ NK cell engager platform. Further data presentations are expected at upcoming conferences.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced a conference call on September 15, 2021, at 2 p.m. CEST to discuss business progress from H1 2021. Key executives participating include CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. The call will be accessible via a live webcast and telephone registration. Innate Pharma is focused on oncology and aims to improve cancer treatment through therapeutic antibodies. The company has alliances with major biopharmaceutical firms and a diverse pipeline of candidates.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced participation at the ESMO 2021 Virtual Congress to present new data regarding monalizumab in combination with durvalumab from the ongoing COAST Phase 2 trial. This research evaluates treatment for unresectable, Stage III non-small cell lung cancer (NSCLC). The results on progression-free survival will be highlighted on September 17, 2021. Additionally, pre-clinical data from Innate's ANKET platform will be showcased on September 18, 2021.
Innate Pharma announces participation in three virtual investor conferences in September 2021. The events include the Goldman Sachs 11th Annual Biotech Symposium on September 7, the Citi 16th Annual Biopharma Virtual Conference on September 8-9, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13. Innate Pharma is focused on oncology and has a strong pipeline of therapeutic antibodies aimed at improving cancer treatment outcomes, with major alliances in the biopharmaceutical sector.
Innate Pharma SA announced the total number of shares outstanding as of August 1, 2021. The company has 79,164,402 ordinary shares and 6,784 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total theoretical voting rights stand at 79,957,342 and exercisable voting rights at 79,938,767. This data complies with French regulations regarding share ownership and voting rights. Innate Pharma focuses on developing therapeutic antibodies aimed at treating cancer, leveraging its expertise in Natural Killer cell biology.
On July 1, 2021, Innate Pharma reported a total of 79,031,980 ordinary shares outstanding, along with 6,796 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total theoretical voting rights are 79,826,480, with 79,807,905 exercisable voting rights. The company, focused on oncology therapeutics, aims to improve patient outcomes using antibody technology. Innate Pharma is backed by partnerships with major players like Bristol-Myers Squibb and AstraZeneca, enhancing its potential in the biotech sector.
Innate Pharma has announced that its FORCE trial, which evaluated avdoralimab for COVID-19 patients with severe pneumonia, did not meet its primary endpoints across all cohorts. The results show no clinical benefit when compared to standard supportive care, leading the company to cease further exploration of avdoralimab in COVID-19. Despite the setback, ongoing trials for avdoralimab in bullous pemphigoid will continue. Additionally, over 100 patients have been safely treated with avdoralimab in related trials without new safety concerns.
Innate Pharma announced promising preliminary data from its Phase 2 TELLOMAK trial of lacutamab for patients with mycosis fungoides expressing KIR3DL2. The results, presented at the 16th International Conference on Malignant Lymphoma, showed a complete response in 1 patient and partial responses in 3, with additional confirmations post-data cutoff. While safety was favorable, the KIR3DL2-non-expressing cohort has not shown adequate responses to advance. The company plans to continue patient enrollment and initiate further studies.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
